Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC "PROMOMED RUS", Russia)

Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC "PROMOMED RUS", Russia)

Introduction. The novel coronavirus infection COVID-19 (Coronavirus Disease 2019) is caused by an enveloped, positive-sense, single-stranded ribonucleic acid (RNA) virus SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2). Favipiravir is the antiviral drug recommended for etiotropic...

Full description

Saved in:
Bibliographic Details
Main Authors: T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2023-05-01
Series:Разработка и регистрация лекарственных средств
Subjects:
favipiravir
covid-19
pharmacokinetics
infusion
Online Access:https://www.pharmjournal.ru/jour/article/view/1494
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1494

Similar Items